Autoimmune hemolytic anemia in patients with systemic lupus erythematosus

Kokori, SIG; Ioannidis, JPA; Voulgarelis, M; Tzioufas, AG; Moutsopoulos, HM

dc.contributor.author	Kokori, SIG	en
dc.contributor.author	Ioannidis, JPA	en
dc.contributor.author	Voulgarelis, M	en
dc.contributor.author	Tzioufas, AG	en
dc.contributor.author	Moutsopoulos, HM	en
dc.date.accessioned	2014-03-01T01:49:46Z
dc.date.available	2014-03-01T01:49:46Z
dc.date.issued	2000	en
dc.identifier.issn	0002-9343	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/25914
dc.subject.classification	Medicine, General & Internal	en
dc.subject.other	CONSENSUS-STUDY-GROUP	en
dc.subject.other	ANTIPHOSPHOLIPID ANTIBODIES	en
dc.subject.other	RHEUMATOLOGY RESEARCH	en
dc.subject.other	CLINICAL-SIGNIFICANCE	en
dc.subject.other	EUROPEAN WORKSHOP	en
dc.subject.other	DISEASE-ACTIVITY	en
dc.subject.other	MANIFESTATIONS	en
dc.subject.other	AUTOANTIBODIES	en
dc.subject.other	SPECIFICITY	en
dc.subject.other	THROMBOSIS	en
dc.title	Autoimmune hemolytic anemia in patients with systemic lupus erythematosus	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2000	en
heal.abstract	PURPOSE: We sought to evaluate the clinical and serologic associations with, and outcomes of, autoimmune hemolytic anemia, as compared with other types of anemia, in patients with systemic lupus erythematosus (SLE). SUBJECTS AND METHODS: We studied 41 consecutive patients with SLE with clinically manifest autoimmune hemolytic anemia, including 27 (66%) in whom hemolysis was the initial disease manifestation. We matched each patient for age and disease duration with a patient with SLE with anemia resulting from a different cause. RESULTS: The 41 patients had a total of 50 episodes of autoimmune hemolytic anemia. The recurrence rate was 4 per 100 person-years. Cases and controls had similar mean (+/- SD) lupus activity indexes (2.1 +/- 1.5 vs 2.4 +/- 1.3, P = 0.5). Patients with autoimmune hemolytic anemia at any time could be distinguished from patients with other causes of anemia, because they were more likely to have elevated titers of IgG anticardiolipin antibodies [odds ratio (OR) = 5.8; 95% confidence interval (CI), 1.4 to 24] and thrombosis (OR = 4.6; 95% CI, 1.0 to 21). Autoimmune hemolytic anemia at the onset of SLE was independently associated with renal involvement (OR = 5.4; 95% CI, 1.0 to 28), thrombocytopenia (OR = 7.3; 95% CI, 1.1 to 4&), and possibly thrombotic episodes during follow-up (OR = 11; 95% CI, 0.8 to 160) when compared with controls with other types of anemia at the onset of SLE. CONCLUSIONS: Autoimmune hemolytic anemia usually occurs at the onset of SLE, and its recurrence rate is low among treated patients. The association with IgG anticardiolipin antibodies and thrombosis suggests that the occurrence of autoimmune hemolytic anemia may define a subgroup of patients with SLE who have characteristic serologic and clinical manifestations. (C) 2000 by Excerpta Medica, Inc.	en
heal.publisher	EXCERPTA MEDICA INC	en
heal.journalName	AMERICAN JOURNAL OF MEDICINE	en
dc.identifier.isi	ISI:000085334500003	en
dc.identifier.volume	108	en
dc.identifier.issue	3	en
dc.identifier.spage	198	en
dc.identifier.epage	204	en